



MISSION

TB ALLIANCE is a not-for-profit organization dedicated to the discovery and development of better, faster-acting, and affordable drugs for tuberculosis. Through innovative science and with partners around the globe, we lead a global effort to ensure development of and equitable access to faster, better tuberculosis cures that will advance global health and prosperity.

We envision a TB-free world. However, the devastating TB pandemic simply cannot be overcome without improved TB treatments.



The global TB burden

TB is a leading global cause of mortality and morbidity, killing 1.4 million each year and robbing millions more of health, hope, and prosperity. TB exacts an insurmountable economic toll on countries, reinforcing poverty in the poorest communities, and leaving men, women, and children financially and physically vulnerable. TB is also the leading infectious cause of death of HIV patients. Today, while people are living longer with HIV, those same patients are increasingly susceptible to dying of TB. TB is a major threat to sustaining progress in AIDS control.

Why new drugs?

The current TB therapy is highly inadequate and is growing increasingly resistant to available therapies.

Today's current treatments take 6-24 months to cure TB. Long treatment times result in poor adherence, which drives the development of drug resistance, including multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB). Treatment for MDR-TB and XDR-TB is even more complex, toxic, and is prohibitively expensive. Due to the cost and complexity of treatment, less than 10% of MDR-TB patients receive proper care, and of those, more than 1 in 3 will still not be cured.

Further, while TB and HIV exhibit a deadly synergy--co-infecting millions--the current TB drugs interact poorly with


certain common HIV medications, severely complicating treatment of co-infected patients. Without new and improved TB drugs, we cannot defeat this deadly disease.

Our pipeline

TB Alliance is leading the world's search for better, faster, and affordable TB cures. Before TB Alliance was established in 2000, there were no new TB drugs in development. Today, the global TB drug pipeline is the largest and most promising it's been in history. The TB Alliance's portfolio includes the first novel TB drug combination, developed from 2 new TB Alliance drug candidates. Also under investigation is a Phase III candidate which could be the first new drug to treat drug-sensitive TB in nearly 50 years, and a robust discovery program – more than 20 active projects in all.

How we operate

TB Alliance is a not-for-profit Product Development Partnership (PDP), an organizational model established to accelerate the development of new technologies to fight public health diseases for which market incentives are lacking. As a PDP, the TB Alliance builds partnerships between the public, private, academic, and philanthropic sectors to drive the development of new TB treatments for underserved markets. We combine the unparalleled research and development expertise of our staff with the skills and resources of our highly accomplished network



“ WITHOUT NEW, FASTER-ACTING TB DRUGS, WE CANNOT ERADICATE THIS GLOBAL KILLER.”

of partners to efficiently leverage the most promising science around the world.

Our commitment to patients

TB Alliance can only achieve its mission if new, faster-acting, and better TB cures are adopted, available, and affordable to those that need them. This commitment—we call it our “AAA Mandate”—is TB Alliance’s explicit pledge to ensure that any new TB treatments developed will be used to benefit people suffering from TB and have maximum impact on the pandemic.

Revolutionizing drug development

TB Alliance isn’t just developing drugs, but is revolutionizing TB drug development with new research models that dramatically speed testing of innovative treatments and save millions of dollars. New drugs are needed, but it is novel combinations of drugs—entirely new regimens—that will enable a quantum leap in TB control and treatment. By developing novel multi-drug regimens, TB Alliance is dramatically reducing the timeline needed to introduce new treatments that will transform TB treatment.

The benefits of new drug regimens include:

- Shorter, simpler, and safer treatment, with better adherence and fewer side effects
- Ability to treat both drug-sensitive and drug-resistant disease with the same regimen, allowing for the global scale-up of therapy

- Makes MDR-TB treatment feasible, with costs 90% less than current therapy,
- TB therapy compatible with HIV/AIDS medications
- Reduced burden to health care systems and treatment suppliers
- Improved treatment outcomes and patient experience

TB Alliance is also accelerating the global TB response through a variety of other innovative scientific, strategic, and community-based initiatives. Importantly, these initiatives include partnerships with TB patients and impacted communities, empowering them with knowledge and skills that accelerate the pace, promise, and capacity of TB research.

Return on investment

Our expertise in TB research & development and established global network has made TB Alliance the partner of choice and an invaluable resource for all those conducting or considering participation in TB drug development. We work in developing regions to help build local capacity, skills, and knowledge. Through this work, we catalyze our collaborators and others to deepen their involvement and investment in TB R&D.

Within TB Alliance, funders’ contributions go further. For every \$1 invested, TB Alliance leverages \$1 in partner funds. Nearly 90% of the funds contributed to TB Alliance are dedicated to program services.

tballiance.org and [@tballiance](https://twitter.com/tballiance)